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Teriparatide for the rapid resolution of delayed healing 
of atypical fractures associated with long-term 
bisphosphonate use
Abstract
Bisphosphonates (BPs) are the most widely used drugs to treat osteoporosis. However, recent reports associated to long-term BP use with 
atypical low-impact fractures and prodromal pain. It is estimated that 26% of the cases of atypical fractures associated with the long-term 
use of BPs show delayed healing or nonunion. Teriparatide [PTH1-34] (TPD) is an anabolic drug shown to be effective in stimulating bone 
formation. The aim was to describe the course of a right diaphyseal femoral fracture sustained by a patient on long-term BP treatment. 
A 57-year-old postmenopausal Caucasian female presented with delayed healing of a right femoral diaphyseal fracture 10 months after 
the fracture, despite having received orthopedic treatment. The fracture was preceded by progressive, severe, and bilateral thigh pain. 
Her medical history included osteopenia that was treated with alendronate over 7 years. On presentation at our clinic, the patient am-
bulated with the aid of a walking cane. The diagnosis was an atypical right femoral fracture associated with long-term alendronate use. 
The levels of the following parameters were measured: mineral metabolism laboratory intact parathormone, 40 ng/mL (rv: 10–65 ng/mL); 
25-hydroxyvitamin D, 40 ng/mL (rv: >30 ng/mL); serum Crosslaps, 318 ng/mL (rv: 80–590 ng/mL); and bone-specific alkaline phosphatase, 
76UI/L (rv: 31–95UI/L)]. Magnetic resonance imaging of the left femur was performed, which revealed a diaphyseal stress fracture. She was 
prescribed 20 µg/day of subcutaneous (s.c.) TPD (PTH1-34, Forteo; Eli Lilly Co., Indianapolis, IN, United States). A computed tomography 
scan performed 3 months later showed that the fracture had healed; the patient was able to resume her usual activities. Twenty micro-
grams per day of s.c. TPD accelerated the healing of the atypical fracture associated with long-term alendronate therapy, allowing a fast 
recovery of ambulation and quality of life.
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Introduction
Osteoporosis is a metabolic bone disease characterized by low bone mass and impaired microarchi-
tecture, which result in greater bone fragility and increased fracture risk (1). Bisphosphonates (BPs) 
are widely used to treat osteoporosis because of their efficacy in reducing osteoporotic fractures and 
increasing bone mineral density (BMD). However, recent reports have associated the long-term use 
of BPs with atypical low-impact fractures and prodromal pain. Such fractures develop in skeletal sites 
predominantly in the cortical bone, most frequently in the diaphysis and subtrochanteric region of the 
femur (2). It is estimated that 26% of the cases of atypical fractures associated with long-term use of 
BPs show delayed healing or nonunion (2). 
Fracture consolidation is a complex process involving the reconstitution of skeletal integrity after 
trauma. Fracture healing time depends on type of fracture, age, presence of chronic disease, and/
or use of medication, and it can take several months before skeletal integrity is restored. Delayed 
healing is a condition where healing time is longer than expected for that particular type of fracture. 
According to the Food and Drug Administration, nonunion is a fracture that is more than nine months 
old and that has not shown radiographic signs of progression toward healing for three consecutive 
months (3).
Teriparatide [PTH 1-34] (TPD) is an approved anabolic drug for treating osteoporosis with a proven effica-
cy in stimulating bone formation in addition to promoting growth factor production for fracture healing. 
Aspenber et al. (4) studied the effect of 20 and 40 µg doses of TPD for 8 weeks on distal radial fracture 
healing (Colles’ fractures) in postmenopausal women. The 20 µg dose proved to be more effective in re-
ducing the average healing time than the 40 µg dose. There is scant information on the possible efficacy 
of TPD in treating delayed union of atypical fractures associated with long-term BP use. 
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The aim of the present communication is to 
describe the clinical course of a patient on 
long-term alendronate therapy and present-
ing with delayed union of a diaphyseal fracture 
of the right femur, which rapidly resolved with 
TPD therapy.
Case Presentation
A 57-year-old post-menopausal Caucasian 
woman presented for consultation because 
of a lack of healing of a diaphyseal fracture of 
the right femur 10 months after the fracture, 
despite having received orthopedic treat-
ment (placement of an intramedullary screw). 
The fracture was preceded by progressive, 
severe, and bilateral thigh pain for 1 year. The 
patient had a relevant history of vulvar cancer 
at the age of 44 years, osteoarthrosis treated 
with glucosamine and chondroitin sulfate, 
and osteopenia treated with alendronate for 
7 years. She had no family history of fractures, 
smoking, excess alcohol consumption, or 
diabetes, and she was not taking glucocor-
ticoids, proton pump inhibitors, or any other 
antiresorptive drug.
On presentation at our clinic, she ambulated 
with the aid of a walking cane. Tests performed 
at our laboratory included the evaluation of 
bone mineral metabolism, BMD, and nuclear 
magnetic resonance imaging (MRI) of the con-
tralateral femur to confirm the presence of a 
diaphyseal fracture of the left femur, which was 
suspected on the initial simple radiograph tak-
en at the time of the fracture. MRI showed a di-
aphyseal stress fracture of the left femur. Treat-
ment with 20 µg/day of subcutaneous (s.c.) 
TPD (Forteo; Eli Lilly Co., Indianapolis, IN, United 
States) was initiated after the patient gave in-
formed consent. After 1 month of treatment, 
the patient reported a significant decrease 
in pain, and no longer needed a walking aid. 
Figure 1 shows the radiographic course of the 
fracture prior to and after TPD therapy. Three 
months after the onset of treatment, multislice 
computed tomography (CT) showed that the 
fracture had healed, and the patient was able 
to resume her usual activities (Figure 2). Table 1 
and 2 show densitometric and mineral metab-
olism values obtained pre- and post-TPD treat-
ment, respectively. No adverse effects associat-
ed with TPD were observed, showing that the 
patient tolerated the drug well.
Discussion
We herein presented a case of delayed union of 
a diaphyseal fracture associated with long-term 
BP use, which resolved after the administration 
of 20 µg/day of s.c. TPD for 3 months. Visekru-
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Table 2. Bone and mineral metabolism 
laboratory results
 Pre-TPD Post-TPD
 (Baseline) (3rd Month)
sCa (8.9–10.4 mg%) 8.8 8.9
sP (2.6–4.4 mg%) 3.2 3.0
25OHD (>30 ng/mL) 40.0 48.2
sCTX (80–590 ng/mL) 318 348
BSAP (31–95 IU/L) 76.0 52.8
iPTH (6–65 pg/mL) 44.0 64.0
uCa (80–250 mg/24 h) 189 131
sCa: serum calcium; sP: serum phosphate; 25OHD: 
25-hydroxyvitamin D; sCTX: serum Crosslaps; BSAP: bone-
specific alkaline phosphatase; iPTH: intact parathormone; uCa: 
urinary calcium; TPD: teriparatide
Table 1. Bone mineral density (DXA; Lunar Prodigy) pre-and post-teriparatide (TPD) treatment 
Lumbar spine: 3.0%
 Pre-TPD (Baseline) g/cm2 T-score Post-TPD (3rd Month) g/cm2  T-score
Lumbar spine 0.928 −2.3 0.939 −2.2
Femoral neck 0.963 −0.1 0.926 −0.5
Total Femur  0.808 −1.6 0.832 −1.4
Femoral neck: 4.2% and total femur: 3.4%
DXA: dual energy X-ray absorptiometry; TPD: teriparatide 
Figure 1. a-d. Radiological healing of the right femur fracture post-teriparatide (TPD) treatment. Radiological healing of a mid-diaphyseal fracture 
in the right femur showing signs of intramedullary osteosynthesis
The first radiograph (a) shows an exuberant callus and persistence of a transverse fracture line. The second (b) and third (c) radiograph show the 
radiological healing evolution after 1 and 3 months of TPD treatment. Post-treatment radiograph (d) shows callus remodeling and no fracture line, 
indicative of fracture healing
a b c d
na et al. (5) and Gomberg et al. (6) reported two 
cases of women with delayed union of bilater-
al diaphyseal femoral fracture associated with 
long-term use of alendronate (≥10 years), who 
achieved fracture consolidation after 1-year 
treatment with 20 µg s.c TPD. Interestingly, un-
like the above cases, the BP-associated atypical 
fracture in our patient consolidated 3 months 
after the administration of 20 µg/day s.c. TPD. 
This suggests that TPD therapy was a more cru-
cial factor of fracture consolidation than time 
since fracture. It must be pointed out that oth-
er factors may have contributed to the shorter 
fracture healing time of the patient presented 
here, such as younger age and shorter duration 
of alendronate therapy, both of which affect the 
bone remodeling rate.
A typical femoral fractures are stress fractures 
associated with BP-induced suppression of 
bone remodeling. In addition to suppressing 
bone remodeling, BPs prevent microcrack re-
pair, thereby increasing microfracture burden 
and reducing crack removal. 
The fracture healing process is completely dif-
ferent in the case of a traumatic or fragility frac-
ture and a stress fracture. In the former case, 
callus formation initiates the formation of a car-
tilage callus, which later undergoes endochon-
dral ossification, resulting in union and miner-
alization. It is only after the stabilization stage 
that bone remodeling begins reconstructing 
the structure of the lamellar bone. In the case 
of stress fractures, the process is initiated only 
through the bone remodeling process so that 
the damaged area is first resorbed and then 
repaired with the newly formed bone (7). 
Sloan et al. (8) experimentally showed that 
TPD significantly increases the area of intra-
cortical resorption and the percentage of 
crack length repair compared with those of 
controls. The observed increase in bone re-
modeling activation during stress fracture 
repair is due to the effect of TPD on osteo-
clasts and osteoblasts. TPD affects osteoclast 
maturation and function, whereas it stim-
ulates osteoblast proliferation, activity, and 
lifespan. The ultimate effect of TPD on stress 
fractures is that it accelerates bone remodel-
ing induced by microcrack formation. Anoth-
er potential intervening factor is long-term BP 
administration, which decreases osteocyte 
apoptosis. It has been posited that osteocyte 
apoptosis initiates bone remodeling after a 
stress fracture. The suppression of osteocyte 
apoptosis suppresses osteoclast activation. 
Nevertheless, further studies are necessary to 
establish whether osteocyte apoptosis leads 
to a delay in stress fracture healing.
In agreement with other cases reported in 
literature, none of the bone remodeling pa-
rameters show excessive suppression of bone 
turnover, though it must be pointed out that 
the markers were evaluated after the fracture 
occurred. We did not observe an increase 
in bone remodeling parameters during TPD 
therapy, as has been observed during osteo-
porosis treatment. This result may be due to 
the effect of BP therapy. Prior treatment with 
BPs would prevent the TPD-induced increases 
in bone remodeling parameters observed in 
treatment-naïve patients (9). This observation 
may be related to the availability of target cells 
for the anabolic action of TPD, which promotes 
bone formation. It has also been reported that 
activation frequency and mineralizing surfaces 
decrease by approximately 90% after 2–3 years 
of alendronate treatment (10). 
Although the present results do not allow draw-
ing definitive conclusions, they suggest that 
TPD therapy was effective in the consolidation 
of a stress fracture after three months. Further 
clinical studies are necessary to determine the 
safety and effectiveness of 20 µg/day of s.c. TPD 
in achieving the healing of diaphyseal femoral 
fractures associated with long-term BP use. Until 
then, TPD should be used with caution.
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Figure 2. Coronal reconstruction computed 
tomography (CT) scan of both femurs (third 
month post-teriparatide treatment). Note the 
presence of metallic osteosynthesis artifacts 
in the right femur.
The image show the course of the mid-di-
aphyseal fracture of the right femur, involving 
bone remodeling, fracture repair callus for-
mation, and fracture healing. Healing of stress 
fracture associated with insufficiency result-
ing in cortical thickening can be observed in 
the mid-diaphysis of the left femur
